Literature DB >> 23304713

Retraction. “Phase II study of the anti–insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer”.

.   

Abstract

Entities:  

Year:  2012        PMID： 23304713     DOI： 10.1200/jco.2012.47.3447

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

Review 1.  Minireview: Were the IGF Signaling Inhibitors All Bad?

Authors:  Heather Beckwith; Douglas Yee
Journal:  Mol Endocrinol       Date:  2015-09-14

Review 2.  Can we unlock the potential of IGF-1R inhibition in cancer therapy?

Authors:  Helen King; Tamara Aleksic; Paul Haluska; Valentine M Macaulay
Journal:  Cancer Treat Rev       Date:  2014-08-04       Impact factor: 12.111

Review 3.  Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung Cancer.

Authors:  Fariz Nurwidya; Sita Andarini; Fumiyuki Takahashi; Elisna Syahruddin; Kazuhisa Takahashi
Journal:  Malays J Med Sci       Date:  2016-05

4.  Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508).

Authors:  Nasser H Hanna; Suzanne E Dahlberg; Jill M Kolesar; Charu Aggarwal; Fred R Hirsch; Suresh S Ramalingam; Joan H Schiller
Journal:  Cancer       Date:  2015-03-04       Impact factor: 6.860

5.  Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

Authors:  Corey J Langer; Silvia Novello; Keunchil Park; Maciej Krzakowski; Daniel D Karp; Tony Mok; Rebecca J Benner; Judith R Scranton; Anthony J Olszanski; Jacek Jassem
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

Review 6.  The Evolution of Therapies in Non-Small Cell Lung Cancer.

Authors:  Vishal Boolell; Muhammad Alamgeer; David N Watkins; Vinod Ganju
Journal:  Cancers (Basel)       Date:  2015-09-09       Impact factor: 6.639

7.  Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.

Authors:  Douglas Yee; Claudine Isaacs; Denise M Wolf; Christina Yau; Paul Haluska; Karthik V Giridhar; Andres Forero-Torres; A Jo Chien; Anne M Wallace; Lajos Pusztai; Kathy S Albain; Erin D Ellis; Heather Beckwith; Barbara B Haley; Anthony D Elias; Judy C Boughey; Kathleen Kemmer; Rachel L Yung; Paula R Pohlmann; Debu Tripathy; Amy S Clark; Hyo S Han; Rita Nanda; Qamar J Khan; Kristen K Edmiston; Emanuel F Petricoin; Erica Stringer-Reasor; Carla I Falkson; Melanie Majure; Rita A Mukhtar; Teresa L Helsten; Stacy L Moulder; Patricia A Robinson; Julia D Wulfkuhle; Lamorna Brown-Swigart; Meredith Buxton; Julia L Clennell; Melissa Paoloni; Ashish Sanil; Scott Berry; Smita M Asare; Amy Wilson; Gillian L Hirst; Ruby Singhrao; Adam L Asare; Jeffrey B Matthews; Nola M Hylton; Angela DeMichele; Michelle Melisko; Jane Perlmutter; Hope S Rugo; W Fraser Symmans; Laura J Van't Veer; Donald A Berry; Laura J Esserman
Journal:  NPJ Breast Cancer       Date:  2021-10-05

8.  Changes of lung tumour volume on CT - prediction of the reliability of assessments.

Authors:  Hubert Beaumont; Simon Souchet; Jean Marc Labatte; Antoine Iannessi; Anthony William Tolcher
Journal:  Cancer Imaging       Date:  2015-10-31       Impact factor: 3.909

9.  IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.

Authors:  Roger Ramcharan; Tamara Aleksic; Wilfride Petnga Kamdoum; Shan Gao; Sophia X Pfister; Jordan Tanner; Esther Bridges; Ruth Asher; Amanda J Watson; Geoffrey P Margison; Mick Woodcock; Emmanouela Repapi; Ji-Liang Li; Mark R Middleton; Valentine M Macaulay
Journal:  Oncotarget       Date:  2015-11-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.